William D. Humphries - 01 Jun 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
01 Jun 2023
Transactions value $
$0
Form type
4
Filing time
05 Jun 2023, 17:12:17 UTC
Previous filing
19 May 2023
Next filing
23 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +4,507 +23% 24,072 02 Jun 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Stock Option (Right to Buy) Award $0 +15,750 $0 15,750 01 Jun 2023 Common Stock 15,750 $8.7 Direct F2, F3
transaction ACRS Restricted Stock Units Award $0 +4,660 $0 4,660 01 Jun 2023 Common Stock 4,660 Direct F1, F2, F4
transaction ACRS Restricted Stock Units Options Exercise $0 -4,507 -100% $0* 0 02 Jun 2023 Common Stock 4,507 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy.
F3 The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date.
F4 The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date.
F5 The shares underlying these restricted stock units vested on June 2, 2023.